Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.

Autor:	Lamb DJ; Immunology & Respiratory, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Rust A; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Rudisch A; Cancer Cell Signalling, Boehringer Ingelheim RCV GmbH & Co KG, A-1121 Vienna, Austria., Glüxam T; Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, 1090 Wien, Austria., Harrer N; Cancer Cell Signalling, Boehringer Ingelheim RCV GmbH & Co KG, A-1121 Vienna, Austria., Machat H; Cancer Cell Signalling, Boehringer Ingelheim RCV GmbH & Co KG, A-1121 Vienna, Austria., Christ I; Immunology & Respiratory, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Colbatzky F; Non-clinical drug safety, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Wernitznig A; Cancer Cell Signalling, Boehringer Ingelheim RCV GmbH & Co KG, A-1121 Vienna, Austria., Osswald A; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Sommergruber W; Cancer Cell Signalling, Boehringer Ingelheim RCV GmbH & Co KG, A-1121 Vienna, Austria.; Biotechnology, University of Applied Sciences, 1030 Vienna, Austria.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2020 Apr 07; Vol. 11 (14), pp. 1257-1272. Date of Electronic Publication: 2020 Apr 07 (Print Publication: 2020).
DOI:	10.18632/oncotarget.27545
Abstrakt:	SYK has been reported to possess both tumour promotor and repressor activities and deletion has been linked to a pro-proliferative / pro-invasive phenotype in breast tumours. It is unclear whether this is a consequence of protein deletion or loss of kinase activity. The SYK inhibitor, BI 1002494, caused no increase in proliferation in breast cancer cells or primary mammary epithelial cells in 2D or 3D cultures, nor changes in proliferation (CD1/2, CDK4, PCNA, Ki67) or invadopodia markers (MMP14, PARP, phospho-vimentin Ser56). BI 1002494 did not alter SYK protein expression. There was no change in phenotype observed in 3D cultures after addition of BI 1002494. Thirteen weeks of treatment with BI 1002494 resulted in no ductal branching or cellular proliferation in the mammary glands of mice. An in silico genetic analysis in breast tumour samples revealed no evidence that SYK has a typical tumour suppressor gene profile such as focal deletion, inactivating mutations or lower expression levels. Furthermore, SYK mutations were not associated with reduction in survival and disease-free period in breast cancer patients. In conclusion, small molecule inhibition of the kinase function of SYK does not contribute to a typical tumour suppressor profile. Competing Interests: CONFLICTS OF INTEREST None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu